Locate Bio - A portfolio of novel orthobiologics
Locate Bio is a developer of next-generation orthobiologic products for use in orthopaedic surgery. The company’s historical expertise is in drug delivery, which it is using to solve some of the issues with existing competitor products, such as the delivery of growth factor for its bone morphogenetic protein 2 (BMP-2) eluting graft substitute LDGraft. The company has three bone graft products and one cartilage product in development, with the first (CertOss) expected to have regulatory clearance in 2022. We value the company’s portfolio of products at £113.1m.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.